Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 26, 2015	Dec. 27, 2014	Dec. 28, 2013
Statement of Cash Flows [Abstract]
Cash and cash equivalents, beginning of period	$ 2,561	$ 5,674	$ 8,478
Cash flows provided by (used for) operating activities:
Net income	11,420	11,704	9,620
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	7,821	7,380	6,790
Share-based compensation	1,305	1,148	1,118
Restructuring and asset impairment charges	354	295	240
Excess tax benefit from share-based payment arrangements	(159)	(122)	(49)
Amortization of intangibles	890	1,169	1,242
(Gains) losses on equity investments, net	(263)	(354)	(425)
Deferred taxes	(1,270)	(703)	(900)
Changes in assets and liabilities:
Accounts receivable	(355)	(861)	271
Inventories	(764)	(98)	563
Accounts payable	(312)	(249)	267
Accrued compensation and benefits	(711)	4	155
Income taxes payable and receivable	386	(286)	1,019
Other assets and liabilities	675	1,391	865
Total adjustments	7,597	8,714	11,156
Net cash provided by operating activities	19,017	20,418	20,776
Cash flows provided by (used for) investing activities:
Additions to property, plant and equipment	(7,326)	(10,105)	(10,711)
Acquisitions, net of cash acquired	(913)	(934)	(925)
Purchases of available-for-sale investments	(8,259)	(7,007)	(12,493)
Sales of available-for-sale investments	2,090	1,227	934
Maturities of available-for-sale investments	6,168	8,944	8,336
Purchases of trading assets	(11,485)	(14,397)	(16,718)
Maturities and sales of trading assets	13,372	13,165	13,677
Investments in loans receivable and reverse repurchase agreements	(2,550)	(150)	(200)
Collection of loans receivable and reverse repurchase agreements	2,116	117	50
Investments in non-marketable equity investments	(2,011)	(1,377)	(440)
Purchases of licensed technology and patents	(120)	(92)	(36)
Other investing	735	704	453
Net cash used for investing activities	(8,183)	(9,905)	(18,073)
Cash flows provided by (used for) financing activities:
Increase (decrease) in short-term debt, net	(474)	235	(31)
Proceeds from government grants	105	104	129
Excess tax benefit from share-based payment arrangements	159	122	49
Issuance of long-term debt, net of issuance costs	9,476	0	0
Proceeds from sales of common stock through employee equity incentive plans	866	1,660	1,588
Repurchase of common stock	(3,001)	(10,792)	(2,147)
Restricted stock unit withholdings	(442)	(332)	(293)
Payment of dividends to stockholders	(4,556)	(4,409)	(4,479)
Collateral associated with repurchase of common stock	325	(325)	0
Increase (decrease) in liability due to collateral associated with repurchase of common stock	(325)	325	0
Other financing	(221)	(199)	(314)
Net cash provided by (used for) financing activities	1,912	(13,611)	(5,498)
Effect of exchange rate fluctuations on cash and cash equivalents	1	(15)	(9)
Net increase (decrease) in cash and cash equivalents	12,747	(3,113)	(2,804)
Cash and cash equivalents, end of period	15,308	2,561	5,674
Cash paid during the year for:
Interest, net of capitalized interest	186	167	204
Income taxes, net of refunds	$ 3,439	$ 4,639	$ 2,874